Who should be really considered as a poor mobilizer in the plerixafor era?

Giovanna Andreola, Anna Vanazzi, Davide Radice, Aleksandra Babic, Cristina Rabascio, Mara Negri, Giovanni Martinelli, Daniele Laszlo

Research output: Contribution to journalArticle

Abstract

Patients with a number of peripheral CD34+ cells ≤20/μL have recently been defined in the literature as "poor mobilizers". We retrospectively reviewed medical records from a total of 248 patients affected by hematological malignancies or solid tumors undergoing peripheral blood stem cell collection following chemotherapy plus G-CSF. On the basis of the CD34+ cell peak in peripheral blood following mobilization therapy, patients were defined as good mobilizers (group A, CD34+ cells ≥20/μL), relative poor mobilizers (group B, CD34+ cells 6 CD34+cells/kg for each transplantation procedure. All patients in group A, 20 patients in group B (57%) and 1 patient in group C (2.7%) were able to collect ≥2.0×10 6 CD34+cells/kg. The multivariate analysis confirmed that more than three lines of previous chemotherapy and a previous autologous PBSC transplantation negatively affect mobilization of CD34+ cells in peripheral blood. Our data suggest that a number of CD34+ cells ≤20/μL does not always result in a failed stem cell collection and in fact in our patient series more than 70% of the patients defined as poor mobilizers have indeed collected the minimum number of 2.0×10 6 CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalTransfusion and Apheresis Science
Volume47
Issue number1
DOIs
Publication statusPublished - Aug 2012

    Fingerprint

Keywords

  • CD34+ cells
  • Poor mobilizers
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology

Cite this